JOHANNESBURG, March 16 (Reuters) - South Africa's drugs regulator SAHPRA said on Tuesday that it had approved a "section 21" emergency use application for the COVID-19 vaccine developed by Pfizer and BioNTech .
SAHPRA added in a statement that the approval was subject to further efficacy and safety surveillance of the vaccine in the country, including against the dominant local coronavirus variant.
(Reporting by Alexander Winning and Wendell Roelf)
((alexander.winning@tr.com; +27 10 346 1076))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments